O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
+11.18%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$9.5B
AUM Growth
+$9.5B
(+8.1%)
Cap. Flow
+$149M
Cap. Flow
% of AUM
1.57%
Top 10 Holdings %
Top 10 Hldgs %
34.99%
Holding
144
New
11
Increased
35
Reduced
32
Closed
10
Top Buys
| 1 |
Cigna
CI
|
$205M |
| 2 |
CLVS
Clovis Oncology, Inc.
CLVS
|
$197M |
| 3 |
Gilead Sciences
GILD
|
$90.1M |
| 4 |
Viatris
VTRS
|
$65.2M |
| 5 |
Biogen
BIIB
|
$52.4M |
Top Sells
| 1 |
Centene
CNC
|
$118M |
| 2 |
HCA Healthcare
HCA
|
$100M |
| 3 |
Pfizer
PFE
|
$99M |
| 4 |
Tenet Healthcare
THC
|
$94.8M |
| 5 |
AGN.PRA
Allergan plc.
AGN.PRA
|
$74.8M |
Sector Composition
| 1 | Healthcare | 92.98% |
| 2 | Financials | 1.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALXN
1
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $471M | 4.94% | 3,871,786 +160,800 | +4% | +$19.6M |
|
|
CELG
2
DELISTED
Celgene Corp
CELG
| $445M | 4.66% | 3,425,777 +293,600 | +9% | +$38.1M |
|
|
3
Biogen
BIIB
$19.4B
| $442M | 4.64% | 1,630,000 +193,100 | +13% | +$52.4M |
|
4
Boston Scientific
BSX
$156B
| $399M | 4.18% | 14,400,000 -911,400 | -6% | -$25.3M |
|
5
Merck
MRK
$210B
| $352M | 3.69% | 5,487,000 -227,900 | -4% | -$14.6M |
|
6
Vertex Pharmaceuticals
VRTX
$100B
| $261M | 2.74% | 2,026,502 -142,698 | -7% | -$18.4M |
|
7
Eli Lilly
LLY
$657B
| $253M | 2.65% | 3,075,000 -255,200 | -8% | -$21M |
|
|
WMGI
8
DELISTED
Wright Medical Group Inc
WMGI
| $246M | 2.58% | 8,946,234 | – | – |
|
9
Regeneron Pharmaceuticals
REGN
$61.5B
| $229M | 2.4% | 466,770 +88,600 | +23% | +$43.5M |
|
10
Agilent Technologies
A
$35.7B
| $226M | 2.37% | 3,814,100 +184,200 | +5% | +$10.9M |
|
11
Amgen
AMGN
$155B
| $224M | 2.35% | 1,302,700 -135,600 | -9% | -$23.4M |
|
12
Edwards Lifesciences
EW
$47.8B
| $217M | 2.28% | 1,839,300 | – | – |
|
13
Puma Biotechnology
PBYI
$254M
| $212M | 2.22% | 2,425,735 +179,810 | +8% | +$15.7M |
|
14
Incyte
INCY
$16.5B
| $209M | 2.2% | 1,663,400 -310,197 | -16% | -$39.1M |
|
|
15
Cigna
CI
$80.3B
| $205M | 2.14% | +1,222,100 | New | +$205M |
|
|
CLVS
16
DELISTED
Clovis Oncology, Inc.
CLVS
| $197M | 2.07% | +2,104,370 | New | +$197M |
|
17
Humana
HUM
$36.5B
| $185M | 1.94% | 770,900 +28,600 | +4% | +$6.88M |
|
18
Elevance Health
ELV
$71.8B
| $173M | 1.82% | 920,618 +58,018 | +7% | +$10.9M |
|
19
AbbVie
ABBV
$372B
| $159M | 1.67% | 2,197,600 +117,600 | +6% | +$8.53M |
|
20
Johnson & Johnson
JNJ
$427B
| $149M | 1.56% | 1,124,400 +239,800 | +27% | +$31.7M |
|
|
21
Gilead Sciences
GILD
$140B
| $147M | 1.54% | 2,073,400 +1,272,500 | +159% | +$90.1M |
|
|
LOXO
22
DELISTED
Loxo Oncology, Inc
LOXO
| $139M | 1.45% | 1,728,000 | – | – |
|
|
AET
23
DELISTED
Aetna Inc
AET
| $135M | 1.41% | 887,900 -424,500 | -32% | -$64.5M |
|
|
ARRY
24
DELISTED
Array Biopharma Inc
ARRY
| $119M | 1.24% | 14,182,900 | – | – |
|
|
25
Viatris
VTRS
$12.3B
| $116M | 1.21% | 2,979,200 +1,679,200 | +129% | +$65.2M |
|